A secondary analysis of a trial that compared liraglutide with placebo in patients with type 2 diabetes at high cardiovascular risk and receiving usual care found that liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo.
The study reported on the prespecified secondary renal outcomes of 9340 patients who were randomly assigned to liraglutide or to placebo for a median 3.84 years. The composite renal outcome—new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease—occurred in 5.7% of patients in the liraglutide group vs 7.2% of those in the placebo group. The rates of renal adverse events were similar in both groups.
Slomski A. Liraglutide May Reduce Diabetic Kidney Disease. JAMA. 2017;318(16):1532. doi:10.1001/jama.2017.15293
Customize your JAMA Network experience by selecting one or more topics from the list below.